BeOne Medicines Ltd
247 hedge funds and large institutions have $14.1B invested in BeOne Medicines Ltd in 2020 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 83 increasing their positions, 88 reducing their positions, and 49 closing their positions.
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
12% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 49
2% more funds holding
Funds holding: 243 → 247 (+4)
0.06% less ownership
Funds ownership: 4.69% → 4.63% (-0.06%)
6% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 88
11% less capital invested
Capital invested by funds: $15.7B → $14.1B (-$1.65B)
73% less call options, than puts
Call options by funds: $12.3M | Put options by funds: $45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$774M |
| 2 |
BlackRock
New York
|
+$94M |
| 3 |
Goldman Sachs
New York
|
+$68.2M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$36.2M |
| 5 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
+$27.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$450M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$163M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$115M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$104M |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$68.8M |
ONC Hedge Fund Activity: Q4 2020 in Review
247 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q4 2020, worth a combined $14.1B — down 11% from $15.7B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new ONC positions and 49 closed out — a net gain of 6 holders — while 83 added to existing stakes and 88 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $774M. The largest seller was Baker Bros. Advisors, cutting an estimated $450M.
- 247 institutional investors held BeOne Medicines Ltd (ONC) as of Q4 2020, up from 243 in Q3 2020.
- Funds reported $14.1B of BeOne Medicines Ltd stock for Q4 2020, down 11% quarter-over-quarter.
- 55 funds opened new BeOne Medicines Ltd positions in Q4 2020 and 49 closed out, a net change of +6 holders.
- The largest BeOne Medicines Ltd buyer in Q4 2020 was Baillie Gifford & Co, an estimated $774M added.
- The largest BeOne Medicines Ltd seller in Q4 2020 was Baker Bros. Advisors, an estimated $450M sold.
Based on aggregated 13F filings for Q4 2020.